Exelixis Aktie
WKN: 936718 / ISIN: US30161Q1040
|
16.11.2026 22:32:02
|
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
Exelixis (NASDAQ:EXEL) has crushed the broader market over the past five years. It has done so mostly thanks to Cabometyx, a cancer medicine that has been its best-selling drug for years. However, things could change for the biotech by the next decade. Exelixis could start facing generic competition for Cabometyx by 2030. Can the company overcome this patent cliff? The answer largely depends on its leading pipeline candidate.
Image source: Getty Images.
Exelixis's strategy in the past has been to develop cancer medicines that target areas of high unmet medical need. That's what it did with Cabometyx. This medicine became the first in renal cell carcinoma (RCC, a type of kidney cancer) to demonstrate statistically significant improvements in three efficacy endpoints: progression-free survival, objective response rate, and, most importantly, overall survival. Cabometyx became a leading medicine in RCC as a result.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Exelixis Inc.
Analysen zu Exelixis Inc.
Aktien in diesem Artikel
| Exelixis Inc. | 60,75 | -2,72% |
|